Abstracts Archive - Page 13 of 2425 - ACR Meeting Abstracts

Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Fizza Zulfiqar¹, Morgan Steele², Sharanya Shre Ezhilarasan Santhi³, Bryanna Singh², Jaisal Brar³, Sumit Raut³, Prami Nakarmi³, Samhitha Bitla Reddy³, Ojo Ayomide³, Bashar Roumia³, Fariha Tareen³, Nathan Crook³, Vanessa Drust³, Ahmed Fawzy Mohamed³, Asad Mohammad Jani³, Jennifer Orejuela³, Siena Captain³, Nikhil Vojalla³, Muhammad Bilal⁴, Rida Fatima⁴, Sanjana Kesireddy³, Paige Misner³, Rishab Prabhu³, Camelia Arsene³, Jawad Bilal⁵ and Jacky Duong³, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²Trinity Health Oakland, Pontiac, MI, ³Trinity Health Oakland, Pontiac, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Southeast Tucson, Clinician Rheumatologist, Tuscon
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…
Abstract Number: 0157 • ACR Convergence 2024
Knowledge and Attitudes About Delta-9-tetrahydrocannabinol (THC) Impact Real-world Practice in an International Group of Rheumatologists
Joanna Zeiger¹, Patti Katz², Mary-Ann Fitzcharles³, Stuart Kassan⁴, Teresa Simon⁵ and Kaleb Michaud⁶, ¹Canna Research Foundation, Boulder, CO, ²UCSF, San Rafael, CA, ³McGill University, Montreal-West, Canada, ⁴National Jewish Health, Denver, CO, ⁵Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatologists care for difficult to manage chronic diseases, necessitating adjustments to new treatments and evolving patient views. When making treatment decisions, rheumatologists incorporate clinical…
Abstract Number: 0141 • ACR Convergence 2024
The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients
Melody Esmaeili¹, Linh Truong², Nicole Ridolfi³, Eugenia Chen⁴ and Maida wong⁵, ¹University of California, Irvine, Orange, CA, ²University of California, Los Angeles, Los Angeles, CA, ³University of California, Irvine, Newport Beach, CA, ⁴Long Beach VA Hospital, Irvine, CA, ⁵Long Beach VA Hospital, Los Angeles, CA
Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…
Abstract Number: 0175 • ACR Convergence 2024
Do Knee Strength and Pain Relate to Developing Stair Climbing Difficulty for Knee Osteoarthritis?
Jason Jakiela¹, Yvonne Golightly², Sydney Liles³, Judy Foxworth⁴ and Daniel White⁵, ¹Winston-Salem State University, Winston-Salem, NC, ²University of Nebraska Medical Center, Omaha, NE, ³University of Delaware, Elkton, MD, ⁴Winston-Salem State University, Elon, NC, ⁵University of Delaware, Newark, DE
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation in older adults, and stair climbing difficulty is often the first-reported limitation. Previous work…
Abstract Number: 0116 • ACR Convergence 2024
Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
Reyhan Kose Cobanoglu¹, Joann Vega², Crystal Burgos³ and Doruk Erkan⁴, ¹Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, ²Hospital for Special Surgery, New York, NY, New York, NY, ³Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, NY
Background/Purpose: Triple aPL-positive (lupus anticoagulant test [LA], anticardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody [aβ2GPI]) patients are at higher risk to develop a severe clinical…
Abstract Number: 0044 • ACR Convergence 2024
Synovial Phosphoproteomic Profiling in Early and Advanced Rheumatoid Arthritis (R4RA Trial) Identifies Specific Signaling Pathways Linked to Distinct Pathotypes
Cankut Cubuk¹, Rachel Lau¹, Vinothini Rajeeve², Pedro Cutillas², Rebecca Hands¹, Liliane Fossati-Jimack¹, Anna Surace¹, Alessandra Nerviani¹, Felice Rivellese¹, Myles Lewis³ and Costantino Pitzalis⁴, and the R4RA Collaborative Group, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, ²Cell Signalling and Proteomics Group, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴QMUL, Bromley Kent, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an incurable autoimmune disease where response to therapy is heterogenous. Clinically indistinguishable RA patients can be classified histo-pathologically into three…
Abstract Number: 0020 • ACR Convergence 2024
CD14 Deficiency Protects Against TLR4/LPS-mediated Inhibition of Osteoclastogenesis
Lance Murphy¹, Kevin Burt², Vu Nguyen³, Baofeng Hu², Robert Mauck³ and Carla Scanzello², ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia
Background/Purpose: Osteoarthritis is associated with bone changes such as subchondral sclerosis, bone marrow lesions, and osteophyte formation (Donel S, 2019). Prior work has demonstrated that…
Abstract Number: 0188 • ACR Convergence 2024
Social Support in African American Women with and Without Systemic Lupus Erythematosus (SLE)
Sarah Smith¹, Chloe Mattila¹, Charmayne M. Dunlop-Thomas², Lusawasra King³, Lori Ann Ueberroth³, Edith Williams⁴, S. Sam Lim⁵, Diane Kamen³, Bethany Wolf³ and Paula Ramos³, ¹Medical University of South Carolina, Charleston, ²Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ³Medical University of South Carolina, Charleston, SC, ⁴University of Rochester School of Medicine and Dentistry, Rochester, ⁵Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately impacts African American women. However, this health disparity population continues to be underrepresented in research. Research suggests that social…
Abstract Number: 0003 • ACR Convergence 2024
CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
Máire F. Quigley¹, Jennifer S. Michaelson¹, Jeffrey Jones¹, Farrukh T. Awan², Geoffrey P. Shouse³, Yue Zhang¹, Todd Shearer¹, Judy Inumerable¹, Irina M. Shapiro¹, Patrick A. Baeuerle¹ and Stephen Wax¹, ¹Cullinan Therapeutics, Inc., Cambridge, ²UT Southwestern Medical Center, Dallas, ³City of Hope Comprehensive Cancer Center, Duarte
Background/Purpose: CD19-directed CAR T cell therapy has been reported to induce profound B cell depletion and deep clinical responses, including drug-free remission, in patients with…
Abstract Number: 0029 • ACR Convergence 2024
Effect of Metformin on the Incidence of Total Knee Replacement: A Systematic Review and Meta-Analysis
Syed Hasan¹, Aali Furqan², Afia Salman³, hira Khan⁴, Sarah Aslam⁵, Alishba Rizvi⁴, Hafsah Alim Ur Rahman³, Muhammad Ahmed Ali Fahim³, Madiha Salman³, Eman Ali³, Yumna Furqan⁶, Shanta bai⁷, Farah Yasmin⁸ and Muhammad Sohaib Asghar⁹, ¹Dow University of Health Sciences, Karachi, PK., Karachi, Sindh, Pakistan, ²University of North Texas Health Science Center (UNT HSC), Texas, TX, ³Dow University of Health Sciences, Karachi, Pakistan, ⁴dow medical college, Karachi, Pakistan, ⁵Dow International Medical College, Karachi, Pakistan, ⁶Texas A&M School of Medicine, Dallas, TX, ⁷Liaquat National Hospital and Medical College, Karachi, Pakistan, ⁸Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, ⁹AdventHealth, Sebring, FL
Background/Purpose: Osteoarthritis (OA) is among the most common debilitating conditions, causing disability and pain in older adults. For end-stage OA, total knee replacement (TKR) is…
Abstract Number: 0040 • ACR Convergence 2024
Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis
Gary Sims¹, Mia Collins², Natalie Pursell³, Teneema Kuriakose¹, Fanyi Jiang⁴, Kristi Moore⁵, Lucie Bertrand⁵, Melissa Lasaro⁵, Jessica Neisen⁶, Scott Manetz⁷, Gabriel Wong⁸, Patrick Riley⁵, Iain McInnes⁹, Kyriakos Konstantinidis¹⁰ and David Close⁸, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Dicerna, Lexington, ⁴Translation and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁵Alexion, AstraZeneca Rare Disease, New Haven, CT, ⁶Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷Clinical Pharmacology and Safety Science, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹⁰Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…
Abstract Number: 0076 • ACR Convergence 2024
Early (3-Month) and Maintained (12-Month) Comparative Effectiveness of 5 Different Classes of Advanced Therapies in a Large Multinational Cohort of Real-World PsA Patients
William Tillett¹, Rieke Alten², Ennio Lubrano³, Khai Jing Ng⁴, Marcus Ngantcha⁵, Inmaculada de la Torre⁴, Dominika Kennedy⁶, Nicola Gullick⁷ and Dennis McGonagle⁸, ¹Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ³Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁴Eli Lilly and Company, Madrid, Spain, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁸National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom
Background/Purpose: The primary objective was to report persistence at 24 months among patients who initiated a new b/tsDMARD. Secondary endpoints included descriptive and comparative effectiveness…
Abstract Number: 0022 • ACR Convergence 2024
Transcriptomic Characterization of Knee Capsule Fibroblasts and Mesenchymal Stromal Cells Reveals an Association Between Flexion Contracture and Alterations in Immune Pathways in People with End-stage OA
Odette Laneuville¹, Daniel Stratis¹, Robert Feibel², Guy Trudel³ and T Mark Campbell⁴, ¹University of Ottawa, Ottawa, ON, Canada, ²The Ottawa Hospital, Ottawa, ON, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴Bruyère Research Institute, Ottawa, ON, Canada
Background/Purpose: Over 10% of adults have symptomatic knee OA but no disease-modifying interventions exist. A flexion contracture (loss of extension; FC) presents in 1/3 of…
Abstract Number: 0055 • ACR Convergence 2024
Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis
Katharine moosic¹, Thomas Olson², Mark Freijat³, samara khalique⁴, Cait Hamele¹, Bryna Shemo¹, Jesse Boodoo⁵, William Baker⁶, Gitanjali Khurana⁷, Matthew Schmachtenberg⁸, Tristin Duffy⁸, Aakrosh Ratan¹, Erika Darrah⁹, Felipe Andrade¹⁰, Marieke Jones⁸, Kristine Olson², David Feith¹, Thomas Loughran¹ and Donald Kimpel¹, ¹University of Virginia, Charlottesville, VA, ²Virginia Commonwealth University, Richmond, VA, ³Flow Rheumatology, Scottsdale, AZ, ⁴Carilion Clinic/ VirginiaTech, Salem, VA, ⁵Sarasota Arthritis Center, Sarasota, FL, ⁶Atrium Health, Charlotte, NC, ⁷University of Virginia, CROZET, VA, ⁸University of Virginia, Charlottesville, ⁹Johns Hopkins University, Baltimore, MD, ¹⁰The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells and frequent somatic activating STAT3 mutations. A…
Abstract Number: 0191 • ACR Convergence 2024
Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care
Alyssa Howren¹, Quan Le Tran¹, Sadaf Sediqi¹, Saadiya Hawa², Eleni Linos¹, Titilola Falasinnu³, Yashaar Chaichian¹ and Julia Simard¹, ¹Stanford School of Medicine, Stanford, CA, ²Weiss Memorial Hospital, Chicago, IL, ³Stanford School of Medicine, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune rheumatic disease whose prognosis varies by race and sex. To understand whether the cognitive processes of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].